Free Trial
NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$9.95 +0.07 (+0.71%)
Closing price 04:00 PM Eastern
Extended Trading
$10.02 +0.07 (+0.70%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Advanced

Key Stats

Today's Range
$9.66
$10.14
50-Day Range
$7.01
$9.95
52-Week Range
$2.36
$10.14
Volume
1.71 million shs
Average Volume
2.93 million shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75
Consensus Rating
Moderate Buy

Company Overview

Trevi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

TRVI MarketRank™: 

Trevi Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 551st out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Trevi Therapeutics has a consensus price target of $21.75, representing about 118.6% upside from its current price of $9.95.

  • Amount of Analyst Coverage

    Trevi Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trevi Therapeutics is -23.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trevi Therapeutics is -23.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 7.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Trevi Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.93% of the outstanding shares of Trevi Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 3.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.93% of the outstanding shares of Trevi Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 3.51%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Trevi Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    25 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 317% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVI Stock News Headlines

Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...tc pixel
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI shares have increased by 141.5% and is now trading at $9.95.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01.
Read the conference call transcript
.

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

Last Earnings
8/07/2025
Today
10/06/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRVI
CIK
1563880
Fax
N/A
Employees
20
Year Founded
2011

Price Target and Rating

High Price Target
$27.00
Low Price Target
$18.00
Potential Upside/Downside
+119.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.44%
Return on Assets
-38.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.42
Quick Ratio
22.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
7.62

Miscellaneous

Outstanding Shares
121,780,000
Free Float
99,492,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
0.74

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners